Navigation Links
Orchid Cellmark Reports Third Quarter 2008 Financial Results

PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today reported its financial results for the third quarter of 2008.

Total revenues were $14.9 million for the third quarter of 2008 compared to $15.6 million for the third quarter of 2007. The decrease in total revenues for the third quarter of 2008 compared to a year ago was largely due to lower revenues in the U.K.

Total U.S.-based revenues rose by 4% over the comparable quarter in 2007, principally due to increases in the U.S. paternity testing business. This was partially offset by lower revenues from forensic casework business as well as a decline in the company's business that generates DNA profiles for the federal CODIS (Combined DNA Index System) and state DNA databases. The decrease in U.K.-based revenues in the quarter compared to a year ago was due to lower volumes of animal DNA testing for scrapie susceptibility and slightly reduced forensics revenues due to adverse exchange rates.

Excluding cost of service revenue, operating expenses for the quarter declined to $5.8 million compared to $6.0 million for the third quarter of 2007 as a result of reduced general and administrative expenses.

Operating loss for the third quarter of 2008 was $1.4 million compared to a $466 thousand loss for the third quarter of 2007. The operating loss increase was principally due to decreases in gross margins in both the U.S. and the U.K. Gross margin for the U.S. business decreased for the third quarter of 2008 compared to the third quarter of 2007 largely as a result of a decline in the average selling prices in the CODIS and forensic casework businesses. Gross margin for the U.K. business in the quarter was adversely impacted by lower margin forensics revenues replacing the DNA testing volumes related to the loss of former LGC business and the buildup of casework management capabilities in the U.K. to service the business the company won under the North West/South West and Wales regional forensics services tender.

Orchid Cellmark reported a net loss of $1.5 million, or $(0.05) per share, for the third quarter of 2008 compared to a net loss of $707 thousand, or $(0.02) per share, for the third quarter of 2007. Net loss for the third quarter of 2008 and 2007 includes charges of $1.1 million and $1.2 million, respectively, for depreciation and amortization.

At September 30, 2008, cash and cash equivalents were $15.9 million.

Thomas Bologna, president and chief executive officer of Orchid Cellmark commented, "Our results for the third quarter reflect a challenging industry environment where pricing pressures, declining U.K. scrapie orders and adverse foreign exchange rates all contributed to the revenue decline, despite increases in forensics casework volume."

Mr. Bologna added, "We did achieve important gains in core business segments, including U.S. paternity, U.S. forensic casework in the Dallas facility and U.K. police force tender revenues. U.K. forensics crime revenue grew by 6% in the third quarter over the second quarter of this year, and would have made up completely for the loss of the LGC-related business had it not been for adverse foreign exchange rates. This is a considerable achievement given that the LGC business represented approximately 40% of U.K. revenues just a year ago."

Mr. Bologna concluded: "The challenges encountered in the third quarter will continue in the fourth quarter of 2008 and put downward pressure on our previously discussed operating targets. Specifically, the impact of the adverse foreign exchange rate, the timing of sample receipts in the U.S., and the continuing buildup of casework management capabilities in the U.K. will influence revenue and gross margin in the fourth quarter. However, we believe the fundamentals of our core business are sound; we have achieved efficiencies in our operations; and we have a strong balance sheet with $15.9 million in cash at the end of the quarter. The DNA identity testing market offers growth opportunities with market dynamics favorable in the U.S. and a changing market in the U.K. that affords us good prospects for gaining market share."

Conference Call Information

A conference call with Orchid Cellmark management will be held on Thursday, October 30, 2008 at 10:00 a.m. EDT. To listen to the conference call, please dial (877) 266-0703 or (706) 643-7682 and ask for the Orchid Cellmark conference call, conference number 70588526. To listen to the live or archived webcast via the Internet, please visit the Investors section of the company's web site at The webcast will be available for replay for 90 days after the conference call.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: expectations regarding Orchid Cellmark's business operations and outlook; the belief that the fundamentals of our core business are sound; and the belief that the DNA testing market offers growth opportunities with market dynamics favorable in the U.S. and a changing market in the UK that affords us good prospects for gaining market share. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, the risk that we are not able to replace the work that we previously provided to several police forces in the U.K. under an arrangement with LGC, the risk that the amount of revenue resulting from the North West/South West and Wales regional tender in the U.K. is not significant, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.

    Investors:                         Media:
    Mary Bashore                       Rick Anderson
    Orchid Cellmark Inc.               The Torrenzano Group
    (609) 750-2324                     (212) 681-1700            

                    Orchid Cellmark Inc. and Subsidiaries
               Condensed Consolidated Statements of Operations
        Three months and nine months ended September 30, 2008 and 2007
                    (In thousands, except per share data)

                                          Three months ended Nine months ended
                                            September 30,     September 30,
                                            2008     2007     2008     2007
      Service revenues                     $14,845  $15,511  $44,404  $45,100
      Other revenues                            27       47      219      222
        Total revenues                      14,872   15,558   44,623   45,322
    Operating expenses:
      Cost of service revenues              10,500   10,054   31,159   29,779
      Research and development                 228      264      654      832
      Marketing and sales                    1,536    1,503    4,659    4,500
      General and administrative             3,588    3,831   12,639   11,747
      Restructuring                            -        (75)     -        (75)
      Amortization of intangible assets        475      447    1,429    1,337
        Total operating expenses            16,327   16,024   50,540   48,120
        Operating loss                      (1,455)    (466)  (5,917)  (2,798)
        Other income, net                      128      301      846      817

        Loss before income tax expense      (1,327)    (165)  (5,071)  (1,981)
    Income tax expense (benefit)               132      542     (117)   1,154
        Net loss                           $(1,459)   $(707) $(4,954) $(3,135)

    Basic and diluted net loss per share    $(0.05)  $(0.02)  $(0.17)  $(0.11)

    Shares used in computing basic and
     diluted net loss per share:            29,935   29,327   29,935   29,323

                    Orchid Cellmark Inc. and Subsidiaries
                    Condensed Consolidated Balance Sheets
                   September 30, 2008 and December 31, 2007
                                (In thousands)

                                                September 30,     December 31,
                                                    2008              2007

    Current assets
      Cash and cash equivalents                    $15,857           $20,918
      Accounts receivable, net                      11,319             9,516
      Inventory                                      1,497             1,443
      Prepaids and other current assets              2,041             2,151
        Total current assets                        30,714            34,028

    Fixed assets, net                                6,399             7,440
    Goodwill                                         9,558             9,519
    Other intangibles, net                           8,185             9,694
    Restricted cash                                    -                 958
    Other assets                                       487               490
        Total assets                               $55,343           $62,129

    Liabilities and Stockholders' Equity:

    Current liabilities
      Accounts payable                              $2,668            $2,027
      Accrued expenses and other current
       liabilities                                   4,297             4,611
      Income taxes payable                             -                 543
      Short-term debt and current portion of
       long-term debt                                  385               428
      Deferred revenue                                 852               964
        Total current liabilities                    8,202             8,573

    Other liabilities                                  284             1,123
        Total liabilities                            8,486             9,696

        Total stockholders' equity                  46,857            52,433

    Total liabilities and stockholders' equity     $55,343           $62,129

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. Saving the wild orchids of Borneo
2. Orchid Cellmark to Present at the 2008 Bank of America Health Care Conference
3. First orchid fossil puts showy blooms at some 80 million years old
4. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
5. Synaptics Reports Record Results for First Quarter of Fiscal 2009
6. GEN reports on novel tools for deciphering biological networks
7. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
8. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
9. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
10. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
11. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
Post Your Comments:
(Date:7/2/2020)... REDWOOD CITY, Calif. (PRWEB) , ... July 01, ... ... stage biotech company, presented its phase 1a findings of Neihulizumab, a biologic for ... annual conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of ...
(Date:6/28/2020)... ... June 25, 2020 , ... Genedata, ... that it has entered into a multi-year contract with Merus N.V., a ... translational and clinical research strategy to discover and develop ground-breaking drugs. The ...
(Date:6/23/2020)... ... 23, 2020 , ... First Aid Africa, a Scottish charity ... and manufacturer of innovative portable renewable energy equipment, have announced the success of ... COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable solar power ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... In most ... used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate ... Dr MA has been using the zebrafish model to investigate the causes of ...
(Date:7/7/2020)... , ... July 06, 2020 , ... ... Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts ... Bio-IT World has hosted an elite awards program, highlighting outstanding examples of how ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... announced that the launch of a new clinical diagnostics immuno-oncology service, ... tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
Breaking Biology Technology: